Document is current

Article History

Received: 16 May 2022

Revised: 16 May 2022

Accepted: 24 July 2022

First Online: 17 August 2022

Declarations

:

: The scientific guarantor of this publication is Felix O. Hofmann.

: F.O.H. received a grant for a 3-month research leave sponsored by the Bavarian Centre for Cancer Research (BZKF), Munich, Germany.V.H. has received honoraria from Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, and Astra-Zeneca. Consulting or advisory board: Merck, Amgen, Roche, Sanofi, SIRTEX, BMS, MSD, Novartis, Boehringer Ingelheim, Servier, Pierre-Fabre, Celgene, and Terumo. Research funding: Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, Sirtex, Bayer, and Servier. Travel accommodation expenses: Merck, Roche, Amgen, SIRTEX, Bayer, and Servier.M.D. serves on the scientific advisory board and performs consultancy services for Keosys Medical Imaging. He has received honoraria (as a speaker) from Siemens Healthineers.L.FvW. has received honoraria from Novartis, Lilly, and Pierre Fabre.T.D. received advisory board honoraria from Novartis and Roche.A.K. has received honoraria and travel support from Merck, Roche, and Amgen and has served on advisory boards for Amgen.M.M. has received grants and non-financial support from EORTC, grants and non-financial support from AIO, grants and non-financial support from German Cancer Aid, and grants and non-financial support from BMBF, during the conduct of the study; personal fees from Falk Foundation; personal fees from Lilly; grants and personal fees from MSD; personal fees from Roche; grants and personal fees from Pfizer; grants, personal fees, and non-financial support from Amgen; grants, personal fees, and non-financial support from Bristol-Myers Squibb; grants and personal fees from Merck Serono; personal fees from MCI Group; and personal fees from Taiho, outside the submitted work.F.Ka. received honoraria from Astellas, Gilead, Pierre Fabre, Servier, Elsevier, MSD, and Novartis.D.P.M. received honoraria from Merck, Amgen, Roche, Servier, Pierre-Fabre, MSD, BMS, Incyte, Lilly, Sanofi, and Onkowissen.S.S. has received honoraria from AMGEN, Bayer, BMS, ESAI, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, and Takeda and has served on advisory boards for AMGEN, Bayer, BMS, ESAI, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, and Takeda. Travel support: AMGEN, Bayer, BMS, ESAI, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, and Takeda.J.W.H. served on an advisory board for Roche and has received honoraria from Roche and travel support from Novartis.All remaining authors declared no conflicts of interest.

: One of the authors has significant statistical expertise.

: Written informed consent was obtained from all patients enrolled in FIRE-3.

: The protocol of the FIRE-3 trial was approved by the ethics committees of all participating centers.

: None of our previous publications or conference contributions reported on volumetric ETS of the FIRE-3 population.

: • Retrospective• diagnostic or prognostic• multicenter study